Regional variations of cardiovascular risk in gout patients: a nationwide cohort study in Korea

Hyun Jung Kim1, Byeongzu Ghang2, Jinseok Kim2

  • 1Department of Preventive Medicine, College of Medicine, Korea University, Seoul, Korea.

PubMed

Insights

Regional variations in cardiovascular risk exist for gout patients in South Korea. Specific regions show increased risks for myocardial infarction and cerebral infarction, necessitating targeted screening.

Area of Science:

  • Cardiovascular epidemiology
  • Rheumatology
  • Public health

Background:

  • Gout is a common condition associated with increased cardiovascular risk.
  • Understanding regional variations in cardiovascular risk among gout patients in South Korea is crucial for public health initiatives.

Purpose of the Study:

  • To investigate the geographical disparities in major cardiovascular events (myocardial infarction, cerebral infarction, cerebral hemorrhage) among patients diagnosed with gout in South Korea.
  • To identify specific regions with elevated cardiovascular risks in the gout population.

Main Methods:

  • A nationwide cohort study utilizing the Korean National Health Insurance claims database and National Health Screening Program data.
  • Inclusion of 231,668 patients aged 20-90 years newly diagnosed with gout after January 2012.
  • Adjustment for pre-diagnosis cardiovascular risk factors to assess relative risks of incident cardiovascular events across different regions.

Main Results:

  • Significant regional differences in cardiovascular risk profiles were observed among gout patients.
  • Gout patients in Jeolla/Gwangju region showed a significantly higher risk of myocardial infarction (aHR, 1.27).
  • Elevated risks for cerebral infarction were noted in gout patients from Gangwon (aHR, 1.38), Jeolla/Gwangju (aHR, 1.41), and Gyeongsang/Busan/Daegu/Ulsan (aHR, 1.37) regions.

Conclusions:

  • Regional variations in cardiovascular risk and associated factors are evident in South Korean gout patients.
  • Healthcare providers should proactively screen gout patients for cardiovascular risk profiles to enable timely diagnosis and management.
  • Geographic-specific risk stratification may improve cardiovascular event prevention strategies in gout patients.
Abstract

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
34
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
119
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
20
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
17
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
25